Cargando…
Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T cells. The major cause of death in heavily pretreated...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599140/ https://www.ncbi.nlm.nih.gov/pubmed/36289682 http://dx.doi.org/10.3390/biomedicines10102420 |
_version_ | 1784816522202447872 |
---|---|
author | Atar, Daniel Mast, Anna-Sophia Scheuermann, Sophia Ruoff, Lara Seitz, Christian Martin Schlegel, Patrick |
author_facet | Atar, Daniel Mast, Anna-Sophia Scheuermann, Sophia Ruoff, Lara Seitz, Christian Martin Schlegel, Patrick |
author_sort | Atar, Daniel |
collection | PubMed |
description | CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T cells. The major cause of death in heavily pretreated NHL patients is lymphoma progression and lymphoma recurrence. Inefficient CAR T cell therapy is the result of the limited potency of the CAR T cell product or is due to loss of the targeted antigen. Target antigen loss has been identified as the key factor that can be addressed stringently by dual- or multitargeted CAR T cell approaches. We have developed a versatile adapter CAR T cell technology (AdCAR) that allows multitargeting. Screening of three different B-lineage lymphoma cell lines has revealed distinct immune target profiles. Cancer-specific adapter molecule combinations may be utilized to prevent antigen immune escape. In general, CD19CAR T cells become non-functional in CD19 negative lymphoma subsets; however, AdCAR T cells can be redirected to alternative target antigens beyond CD19, such as CD20, CD22, CD79B, and ROR-1. The capability to flexibly shift CAR specificity by exchanging the adapter molecule’s specificity broadens the application and significantly increases the anti-leukemic and anti-lymphoma activity. The clinical evaluation of AdCAR T cells in lymphoma as a new concept of CAR T cell immunotherapy may overcome treatment failure due to antigen immune escape in monotargeted conventional CAR T cell therapies. |
format | Online Article Text |
id | pubmed-9599140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95991402022-10-27 Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas Atar, Daniel Mast, Anna-Sophia Scheuermann, Sophia Ruoff, Lara Seitz, Christian Martin Schlegel, Patrick Biomedicines Article CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T cells. The major cause of death in heavily pretreated NHL patients is lymphoma progression and lymphoma recurrence. Inefficient CAR T cell therapy is the result of the limited potency of the CAR T cell product or is due to loss of the targeted antigen. Target antigen loss has been identified as the key factor that can be addressed stringently by dual- or multitargeted CAR T cell approaches. We have developed a versatile adapter CAR T cell technology (AdCAR) that allows multitargeting. Screening of three different B-lineage lymphoma cell lines has revealed distinct immune target profiles. Cancer-specific adapter molecule combinations may be utilized to prevent antigen immune escape. In general, CD19CAR T cells become non-functional in CD19 negative lymphoma subsets; however, AdCAR T cells can be redirected to alternative target antigens beyond CD19, such as CD20, CD22, CD79B, and ROR-1. The capability to flexibly shift CAR specificity by exchanging the adapter molecule’s specificity broadens the application and significantly increases the anti-leukemic and anti-lymphoma activity. The clinical evaluation of AdCAR T cells in lymphoma as a new concept of CAR T cell immunotherapy may overcome treatment failure due to antigen immune escape in monotargeted conventional CAR T cell therapies. MDPI 2022-09-28 /pmc/articles/PMC9599140/ /pubmed/36289682 http://dx.doi.org/10.3390/biomedicines10102420 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Atar, Daniel Mast, Anna-Sophia Scheuermann, Sophia Ruoff, Lara Seitz, Christian Martin Schlegel, Patrick Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas |
title | Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas |
title_full | Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas |
title_fullStr | Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas |
title_full_unstemmed | Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas |
title_short | Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas |
title_sort | adapter car t cell therapy for the treatment of b-lineage lymphomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599140/ https://www.ncbi.nlm.nih.gov/pubmed/36289682 http://dx.doi.org/10.3390/biomedicines10102420 |
work_keys_str_mv | AT atardaniel adaptercartcelltherapyforthetreatmentofblineagelymphomas AT mastannasophia adaptercartcelltherapyforthetreatmentofblineagelymphomas AT scheuermannsophia adaptercartcelltherapyforthetreatmentofblineagelymphomas AT ruofflara adaptercartcelltherapyforthetreatmentofblineagelymphomas AT seitzchristianmartin adaptercartcelltherapyforthetreatmentofblineagelymphomas AT schlegelpatrick adaptercartcelltherapyforthetreatmentofblineagelymphomas |